Case Report

Modern Rheumatology

pp 1-4

First online:

Successful leukocytapheresis therapy in a patient with rheumatoid arthritis on maintenance hemodialysis

  • Keisuke MaeshimaAffiliated withDepartment of Internal Medicine I, Faculty of Medicine, Oita University
  • , Masataka TorigoeAffiliated withDepartment of Internal Medicine I, Faculty of Medicine, Oita University
  • , Mikako IwakuraAffiliated withDepartment of Internal Medicine I, Faculty of Medicine, Oita University
  • , Kunitoshi YamanakaAffiliated withDepartment of Internal Medicine, Nakatsu Daiichi Hospital
  • , Koji IshiiAffiliated withDepartment of Internal Medicine I, Faculty of Medicine, Oita University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

We report the case of a 44-year-old female undergoing maintenance hemodialysis in whom early-phase rheumatoid arthritis (RA) was successfully treated by leukocytapheresis (LCAP). The effects of prednisone, tacrolimus, and etanercept were limited, but LCAP was highly effective and its efficacy continued even after cessation of LCAP. Moreover, remission was maintained for 2 years after discontinuation of medication. LCAP may be an important treatment option for RA patients with end-stage renal failure who are on hemodialysis.

Keywords

Leukocytapheresis (LCAP) Rheumatoid arthritis Hemodialysis Drug-free remission